Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d
Made exclusively from LactoSorb Resorbable Copolymer.
The Stryker Cross-Screw System offers the surgeon a simple and secure method for ACL reconstruction utilizing soft tissue grafts. The Stryker Cross-Screw System provides the latest technology in femo
Medicine Products:(Date:5/16/2008)... sufferers gain benefit from calcitriol, an oral f...-- Taking activated vitamin D may cut the risk of ...idney disease by about one quarter, a new study su... 1,400 patients, those being treated with calcitri... overall risk of death lowered by 26 percent when ...
(Date:5/16/2008)...vices for Frail Seniors and People With,Disabiliti...e/ -- Thousands of,homecare workers across the sta...oposed cuts to hours of service, wages and benefit...nerable workers and the,people they serve deeper i...ices for seniors and people with disabilities from...
(Date:5/16/2008)...ment for National HIV Vaccine Awareness Day, May,1...Twenty-six years into the,AIDS epidemic, someone i...U.S. On Sunday, May 18, HIV Vaccine Awareness Day,... National Institute of Allergy and Infectious,Dise...ive, urges everyone,to help end the AIDS epidemic ...
(Date:5/16/2008)...ire/ -- Huntsworth plc (LSE: HNT), "the Group",a ...are communications,group headquartered in London, ...t to the Group,s performance in the first quarter ...tatement follows below., 15 May 2008, ... Interim Management Statement, Re...
Breaking Medicine News(10 mins):Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4(Date:5/15/2008)...unt of research reflects depth and breadth of, co...p new treatments for divers... impact of Zometa(R), the leading IV, bisphosphona...reast cancer, - Four oral sessions to feature RAD...f mTOR, including first results of RECORD-1 study ...
(Date:5/15/2008)...TOULOUSE, France, May 15 /- Cerenis,T...eutical company,developing HDL-related compounds f...iseases, today announced that it has completed a P...any,s lead product candidates.,CER-002 is a peroxi...specific agonist in development for the treatment ...
(Date:5/15/2008)...Remains for an Antiplatelet Therapy that, Combined...ination of Plavix/Iscover and Aspirin, Accordi...AM, Mass., May 15 /- Decision Resourc...ry firms for pharmaceutical and,healthcare issues,...ers,improvement in patient compared to Sanofi-Aven...
(Date:5/15/2008)...15 /- Omega 3 fatty acids bound to,ph... credible natural,alternative and may have benefic... in vivo French study reveals. While several studi...hyperactivity, French researchers have,hypothesize...ffects on,impulse control., These research findin...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Ceramic heal thyself 2960 1Ceramic heal thyself 2960 2Accenx Technologies Announces New Leadership in Sales and Marketing Division 17219 1Accenx Technologies Announces New Leadership in Sales and Marketing Division 17219 221st Congress of the College of Neuropsychopharmacology 17215 121st Congress of the College of Neuropsychopharmacology 17215 2Computer Program Helps COPD Patients Monitor Breathing 17212 1Computer Program Helps COPD Patients Monitor Breathing 17212 2... 2007 /PRNewswire-FirstCall/ -- Boston,Scientific ...rticle,in the Journal of of Cardiology (JACC) revi...tes the Company,s second-generation,TAXUS(R) Liber...icle in the April 24 edition of JACC concluded tha...e of the TAXUS Liberte Stent,system compared to th...
...--Jun 4, 2007 - Pfizer announced today that,axitin... inhibitor,of VEGFR 1, 2,3 (vascular endothelial g...itabine showed a trend towards prolonged,overall s...cancer,compared with gemcitabine alone, according...ial., These data were presented at the 43rd Americ...
Other Medicine Technology:Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 2Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 3Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 4New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 2New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 3New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 4